Results 1 - 4 of 4

• Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a V??9V??2 T lymphocyte agonist in patients with solid tumors, Cancer Immunology, Immunotherapy

  [DOI: 10.1007/s00262-010-0879-0]
  
• Phase-I study of Innacell ???????, an autologous cell-therapy product highly enriched in ??9??2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma, Cancer Immunology, Immunotherapy

  [DOI: 10.1007/s00262-008-0491-8]
  
• V??9V??2 T cells as a promising innovative tool for immunotherapy of hematologic malignancies, Oncology Reviews

  [DOI: 10.1007/s12156-010-0054-z]
  
• Fighting cancer with inflammation, Science-Business eXchange

  [DOI: 10.1038/scibx.2011.388]